BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

...T cell responses by excluding any T cell epitopes from tau and instead inducing a tau-independent...
...still coming.The semorinemab news was the first major blow the tau hypothesis, which maintains that tau...
...target intracellular and extracellular tau? AC Immune’s vaccine will test the former; its small molecule tau...
BioCentury | Feb 3, 2021
Product Development

Big gain for Cassava on little efficacy data in Alzheimer’s

...protein hypothesized to misfold in the brains of Alzheimer’s patients, contributing to the misfolding of tau...
BioCentury | Jan 30, 2021
Regulation

Biogen’s remaining options to bolster aducanumab’s case as PDUFA is extended

...week 78. Submit new correlation analysis.Possible workaround 2: Submit more data on other biomarkers, particularly tau...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting histone trimethylation to treat Alzheimer’s

...an SGK1 antagonist tool compound improved performance on those behavioral tests and lowered levels of phosphorylated tau...
...leukemia protein (MLL1; MLL; HRX; KMT2A); serum/glucocorticoid regulated kinase 1 (SGK1); microtubule-associated protein τ (tau; MAPT; FTDP-17)EXPERIMENTAL...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...adds a second PET agent to image tau...
...we’ve seen that if they don’t have tau...
...trial, Lilly sought patients with a “Goldilocks tau”...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...tau-targeting Alzheimer’s disease candidate. Two were optimistic.While tau...
...big Alzheimer’s target behind amyloid, the first tau...
...target. Another issue is whether the forms of tau...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...can include structures that contain DNA; may comprise only one type of biomolecule, as in tau...
...Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture InvestmentsCEO: Cary PfefferPatents: UndisclosedTARGETStau  (MAPT; FTDP-17...
BioCentury | Nov 21, 2020
Product Development

Could an approval of Biogen’s Alzheimer’s therapy still be an option?

...the misfolding and aggregation of the protein tau...
...think Biogen should correlate changes in phosphorylated tau...
BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

...in Alzheimer's disease. Selina, you've been following tau...
...I know you've written a lot about tau...
...of tau antibodies, and other types of tau...
BioCentury | Nov 10, 2020
Product Development

First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target

...decrease tau aggregation as measured by PET imaging.“Tau...
...tau, based on the hypothesis that misfolded tau...
...MAPT; FTDP-17) – Microtubule-associated protein tau Selina Koch Genentech Inc. AC Immune S.A. Microtubule-associated protein tau (tau) (MAPT) (FTDP-17) Neurology Alzheimer's...
Items per page:
1 - 10 of 685